MCW Master Predict (Profile Related Evidence Determining Individualized Cancer Therapy)
Medical College of Wisconsin Master Predict (Profile Related Evidence Determining Individualized Cancer)
1 other identifier
observational
10,000
1 country
1
Brief Summary
The study is an observational trial for patients undergoing cancer-related interventions and therapy at Medical College of Wisconsin Cancer Center. Projects under this protocol will use patient data that will be collected both retrospectively and prospectively. It will also enable prospective sample collection for specific cancer-related studies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2022
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 19, 2022
CompletedFirst Submitted
Initial submission to the registry
March 24, 2023
CompletedFirst Posted
Study publicly available on registry
April 6, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2027
August 17, 2025
August 1, 2025
5 years
March 24, 2023
August 15, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
Number of subjects receiving precision therapies providing biospecimens of any kind.
Precision therapies are targeted against specific genomic mutations.
One year
Number of subjects not receiving precision therapies and providing biospecimens.
Precision therapies are targeted against specific genomic mutations.
One year
Eligibility Criteria
Patients aged 18 years and older who were previously or are currently receiving care for a cancer-related condition at MCW/FH. Newly diagnosed cancer patients at MCW/FH will also be considered. Patients must be willing and able to give informed consent for any prospective data or specimen collection.
You may qualify if:
- Subjects aged 18 years and older who were previously or are currently receiving care for a cancer-related condition at MCW/FH.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Biospecimen
A primary objective is to enable prospective collection of blood, urine, and other tissues for the purpose of identifying markers of outcomes, including, but not limited to genomic, immunologic, and pharmacologic profile testing from patients with cancer and related disorders at MCW/FH.
MeSH Terms
Conditions
Study Officials
- PRINCIPAL INVESTIGATOR
Sameem Abedin, MD
Medical College of Wisconsin
- PRINCIPAL INVESTIGATOR
Razelle Kurzrock, MD
Medical College of Wisconsin
- PRINCIPAL INVESTIGATOR
Mary M. Horowitz, MD, MS
Medical College of Wisconsin
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
March 24, 2023
First Posted
April 6, 2023
Study Start
December 19, 2022
Primary Completion (Estimated)
December 1, 2027
Study Completion (Estimated)
December 1, 2027
Last Updated
August 17, 2025
Record last verified: 2025-08
Data Sharing
- IPD Sharing
- Will not share